A detailed history of Catalyst Funds Management Pty LTD transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 900 shares of TVTX stock, worth $15,417. This represents 0.0% of its overall portfolio holdings.

Number of Shares
900
Holding current value
$15,417
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.89 - $15.21 $7,101 - $13,689
900 New
900 $12.6 Million
Q2 2024

Dec 17, 2024

BUY
$5.26 - $8.28 $68,906 - $108,467
13,100 Added 1455.56%
14,000 $115 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.1B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Catalyst Funds Management Pty LTD Portfolio

Follow Catalyst Funds Management Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Funds Management Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Funds Management Pty LTD with notifications on news.